Diabetes Clinical Trials in Boston

Showing 441-460 of 610 trials

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

NCT00212329

Type 1 diabetes is a condition that is caused in part by an abnormality of the immune system which occurs when T cells, which are part of the immune system, damage the insulin secreting cells (islet cells) in the pancreas. Although it is known that T cells are important mediators of the disease, progress in the development of reliable T cell assays has been modest. The purpose of this study is to learn which T cell assays are most reliable and reproducible so that the investigators can improve their understanding about how type 1 diabetes occurs.

Type 1 Diabetes Mellitus

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)100 participantsStarted Sep 2005

Los Angeles, California, United States • San Francisco, California, United States • Stanford, California, United States +11 more locations

COMPLETED< 1 mile

G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator

NCT02696252

Comparison of G5® Mobile Continuous Glucose Monitoring System Accuracy When Using an Automated Applicator vs. a Manual Sensor Applicator

Diabetes Mellitus

DexCom, Inc.97 participantsStarted Jan 2016

Escondido, California, United States • Idaho Falls, Idaho, United States • Boston, Massachusetts, United States +1 more locations

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator

Diabetes Trials in Other Cities

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Synchronization to Improve Non-Adherence to Cardiovascular Medications

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Other Conditions in Boston